trending Market Intelligence /marketintelligence/en/news-insights/trending/FvmxzFW2v1FnZveiTTeoBA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US FDA puts Kura's head and neck cancer drug tipifarnib on fast track

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA puts Kura's head and neck cancer drug tipifarnib on fast track

Kura Oncology Inc. has received the U.S. Food and Drug Administration's fast-track designation for cancer drug tipifarnib in patients with a specific mutation of head and neck squamous cell carcinoma.

The FDA grants fast-track designation for drugs that treat life-threatening diseases with an unmet medical need. The tag allows the application to progress more quickly through the regulatory process with frequent collaboration with the agency.

Tipifarnib inhibits an enzyme that is thought to lead to tumor formation and is linked to the pathway that KRAS inhibitors also block. Kura in 2018 announced that tipifarnib shrank tumors in nine out of 11 patients with head and neck squamous cell carcinoma with a mutation of the gene HRAS.

Kura expects to complete enrollment of patients in a clinical trial for tipifarnib in head and neck cancer patients in 2021 after earlier delays at certain sites.